Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram.
BACKGROUND
Generalized anxiety disorder (GAD) is a common disorder in older adults, which has been linked to hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in this age group. The authors examined whether treatment of GAD in older adults with a selective serotonin reuptake inhibitor (SSRI) corrects this HPA axis hyperactivity.


METHODS
The authors examined adults aged 60 years and older with GAD in a 12-week randomized controlled trial comparing the SSRI escitalopram with placebo. The authors collected salivary cortisol at six daily time points for 2 consecutive days to assess peak and total (area under the curve) cortisol, both at baseline and posttreatment.


RESULTS
Compared with placebo-treated patients, SSRI-treated patients had a significantly greater reduction in both peak and total cortisol. This reduction in cortisol was limited to patients with elevated (above the median) baseline cortisol, in whom SSRI-treated patients showed substantially greater reduction in cortisol than did placebo-treated patients. Reductions in cortisol were associated with improvements in anxiety. Additionally, genetic variability at the serotonin transporter promoter predicted cortisol changes.


CONCLUSIONS
SSRI treatment of GAD in older adults reduces HPA axis hyperactivity. Further research should determine whether these treatment-attributable changes are sustained and beneficial.
Lenze
Eric J
EJ
Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA. lenzee@wustl.edu
Mantella
Rose C
RC
Shi
Peichang
P
Goate
Alison M
AM
Nowotny
Petra
P
Butters
Meryl A
MA
Andreescu
Carmen
C
Thompson
Paul A
PA
Rollman
Bruce L
BL
D000368:Aged; D000369:Aged, 80 and over; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D015283:Citalopram / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D006801:Humans; D006854:Hydrocortisone / Q000032:analysis* / Q000378:metabolism; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000503:physiopathology; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D012463:Saliva / Q000737:chemistry; D050486:Serotonin Plasma Membrane Transport Proteins / Q000187:drug effects / Q000235:genetics; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D015283:Citalopram; D006854:Hydrocortisone; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors; C493230:SLC6A4 protein, human
Psychoneuroendocrinology. 2008 May;33(4):517-29
18337016
Am J Geriatr Psychiatry. 2010 Jan;18(1):42-50
20094017
Life Sci. 1997;61(22):2239-46
9393943
Expert Rev Neurother. 2008 Jan;8(1):111-20
18088204
Neuroimage. 2005 Jul 1;26(3):891-9
15955499
Rev Neurosci. 1999;10(2):117-39
10658955
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14158-63
16983099
Biol Psychiatry. 2008 Oct 15;64(8):701-7
18571624
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17312-5
15574496
JAMA. 2009 Jan 21;301(3):295-303
19155456
Psychoneuroendocrinology. 2008 Jul;33(6):773-81
18407426
Neuron. 2007 Dec 6;56(5):924-35
18054866
J Consult Clin Psychol. 2003 Apr;71(2):309-19
12699025
Psychiatry Res. 2009 Aug 30;173(2):121-7
19559575
Mol Psychiatry. 2007 Jun;12(6):544-55
17353910
Arch Gen Psychiatry. 2007 Jul;64(7):810-8
17606815
Am J Geriatr Psychiatry. 2006 Aug;14(8):684-93
16861373
Am J Psychiatry. 2000 Jan;157(1):89-95
10618018
Psychoneuroendocrinology. 2008 Feb;33(2):246-54
18082975
Biol Psychiatry. 2004 Jul 15;56(2):113-20
15231443
J Clin Endocrinol Metab. 1996 Jul;81(7):2468-73
8675562
Psychoneuroendocrinology. 2001 Apr;26(3):225-40
11166486
Behav Res Ther. 1990;28(6):487-95
2076086
J Neurosci. 1994 May;14(5 Pt 1):2893-903
8182446
Psychoneuroendocrinology. 2003 Oct;28(7):916-31
12892658
Am J Geriatr Psychiatry. 2006 Apr;14(4):325-33
16582041
Am J Geriatr Psychiatry. 2006 Apr;14(4):334-42
16582042
Am J Psychiatry. 2006 Dec;163(12):2164-9
17151169
Nat Neurosci. 2005 Jun;8(6):828-34
15880108
Psychoneuroendocrinology. 2005 Jan;30(1):80-91
15358445
Am J Geriatr Psychiatry. 2007 Jun;15(6):522-9
17545451
Dialogues Clin Neurosci. 2006;8(4):433-44
17290801
Nat Neurosci. 2005 Jan;8(1):20-1
15592465
J Affect Disord. 2008 Mar;106(3):307-13
17727959
J Neurosci. 2006 Apr 19;26(16):4415-25
16624961
Mol Psychiatry. 2009 Jan;14(1):95-105
17912249
Biol Psychiatry. 2007 Sep 1;62(5):479-86
17481591
Biol Psychiatry. 2008 May 1;63(9):847-51
18005940
Am J Psychiatry. 2006 Sep;163(9):1588-93
16946185
J Affect Disord. 2008 Aug;109(3):233-50
18155775
J Psychiatr Res. 2004 May-Jun;38(3):305-12
15003436
Am J Geriatr Psychiatry. 2006 Apr;14(4):295-8
16582037
Psychosom Med. 2007 Nov;69(8):762-8
17942837
Br J Med Psychol. 1959;32(1):50-5
13638508
Am J Psychiatry. 2004 Nov;161(11):2081-90
15514410
Neuroendocrinology. 1995 Apr;61(4):464-70
7783860
J Psychiatr Res. 2009 May;43(8):777-83
19054531
N Engl J Med. 1998 Jan 15;338(3):171-9
9428819